SCHEMBL424064

SCHEMBL424064

CCN1COCNC1=N[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424063 1.00 CHRNB2 (0.31) CHRNB2CHRNA4
SCHEMBL419252 0.88
SCHEMBL419251 0.88
SCHEMBL426321 0.85 MEN1 (0.36)
SCHEMBL426320 0.85 MEN1 (0.36)
SCHEMBL425614 0.82
SCHEMBL425613 0.82
SCHEMBL421339 0.81
SCHEMBL421338 0.81
SCHEMBL424753 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022053-A1 Oxadiazine Derivatives SYNGENTA CROP PROTECTION, INC. (US) 2012-01-26 US disclosed
US-7655650-B2 Oxadiazine derivatives Syngenta Corporation (US) 2010-02-02 US disclosed
US-20070219188-A1 Oxadiazine Derivatives SYNGENTA CROP PROTECTION, INC. (US) 2007-09-20 US disclosed
US-20030232821-A1 Oxadiazine derivatives MAIENFISCH PETER (CH) 2003-12-18 US disclosed
EP-0580553-B1 Oxadiazine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2003-11-26 EP disclosed
US-6627753-B1 Agricultural insecticides SYNGENTA INVESTMENT CORPORATION 2003-09-30 US disclosed
US-6376487-B1 SELECTIVE INSECTICIDES FOR KILLING FLIES, ROACHES, WEEVILS, AND OTHER PESTS; FOR USE ON COTTON, LEGUMES, FRUITS, CEREALS, BEANS, AND OTHER CROPS SYNGENTA INVESTMENT CORP. 2002-04-23 US disclosed
US-6022871-A INSECTICIDES NOVARTIS CORPORATION (US) 2000-02-08 US disclosed
US-5852012-A Oxadiazine derivatives NOVARTIS CORPORATION (US) 1998-12-22 US disclosed
EP-0580553-A2 Oxadiazine derivatives CIBA-GEIGY AG (CH) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219188-A1 Oxadiazine Derivatives CBR3, AOC3, AOC2 CHRNB2 1127/4885CHRNA4 1839/4885
US-20030232821-A1 Oxadiazine derivatives HCN1, SCO2, AOC3 CHRNB2 215/4885CHRNA4 370/4885
US-20120022053-A1 Oxadiazine Derivatives CBR3, AOC3, AOC2 CHRNB2 1127/4885CHRNA4 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.